8-K: Neuronetics Announces CFO Transition, Reaffirms Guidance

Neuronetics, Inc. announced the departure of its CFO, Steven E. Pfanstiel, effective May 1, 2026, and reaffirmed its fiscal year 2026 financial guidance.

Summary

• Neuronetics, Inc. is announcing a change in its Chief Financial Officer role, with Steven E. Pfanstiel resigning effective May 1, 2026, to pursue an external opportunity.
• The company has initiated a search for a successor to Mr. Pfanstiel.
• Neuronetics has reaffirmed its financial guidance for fiscal year 2026, which was initially provided during its fourth quarter 2025 earnings call on March 17, 2026.
• The company also entered into an Executive Consulting and Release Agreement with former CEO Keith J. Sullivan, who will provide consulting services through March 31, 2027, without additional compensation, while continuing to vest in his equity awards.
• Additionally, Neuronetics is implementing a workforce reduction impacting up to 5% of its employees, expected to be completed by mid-year 2026, to optimize its cost structure.
• This workforce reduction is anticipated to incur restructuring charges of approximately $0.2 million in the second quarter of 2026, with projected annualized cost savings of $2.5 million to $3.0 million, beginning primarily in the third quarter of 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing due to the workforce reduction and CFO departure, balanced by the reaffirmation of financial guidance and cost-saving initiatives.

Positives

• Reaffirmation of fiscal year 2026 financial guidance indicates management's confidence in meeting previously stated targets.
• Projected annualized cost savings of $2.5 million to $3.0 million from workforce optimization.
• Continued vesting of equity awards for former CEO Keith J. Sullivan, aligning his interests during the consulting period.
• The departure of CFO Steven E. Pfanstiel is not due to any dispute or disagreement with the company.

Negatives

• Workforce reduction impacting up to 5% of employees.
• Incurrence of approximately $0.2 million in restructuring charges for severance and related costs in Q2 2026.
• Departure of the Chief Financial Officer, Steven E. Pfanstiel, requiring a search for a successor.

Risks

• The company's ability to achieve or sustain profitable operations due to its history of losses.
• Reliance on the sale and usage of the NeuroStar Advanced Therapy System for revenue generation.
• Challenges in retaining talent.
• Availability of coverage and reimbursement from third-party payors for treatments.
• Physician and patient demand for treatments.
• Developments in competing technologies and therapies.
• Potential effects of evolving and/or extensive government regulation.
• The company's ability to maintain positive cash flow.

Future Outlook

The company has reaffirmed its financial guidance for fiscal year 2026, previously provided on March 17, 2026. Specific details of the guidance are not provided in this filing but are referenced as being consistent with prior communications.

Management Comments

• Steven E. Pfanstiel will depart his role as Executive Vice President, Chief Financial Officer, and Treasurer to pursue an opportunity outside the Company.
• Mr. Pfanstiel's decision to resign is not the result of any dispute or disagreement with the Company or the Company's management or Board on any matter relating to the Company's operations, policies, or practices.
• Keith J. Sullivan will provide specified consulting services to the Company through March 31, 2027, in connection with his retirement.

Industry Context

StockSavvy.ai notes that workforce reductions and cost optimization measures are becoming increasingly common in the medical technology sector as companies navigate market dynamics and strive for profitability. Reaffirming financial guidance amidst these changes suggests a focus on operational efficiency and meeting investor expectations.

Management Changes

Related Party Transactions

• Executive Consulting and Release Agreement with former CEO Keith J. Sullivan, who will provide consulting services through March 31, 2027, and continue to vest in his outstanding equity awards.

Stakeholder Impact

• Shareholders: Reaffirmed guidance may provide stability, but workforce reduction and CFO departure could signal underlying challenges.
• Employees: Up to 5% of employees will be impacted by the workforce reduction.
• Management: The company is undergoing a transition in its Chief Financial Officer role.

Next Steps

• Complete the search for a successor to CFO Steven E. Pfanstiel.
• Complete the workforce reduction by mid-year 2026.
• Begin realizing net cost savings primarily in the third quarter of 2026.
• Continue consulting services with Keith J. Sullivan through March 31, 2027.

Key Dates

Recommendation

The reaffirmation of financial guidance is positive, but the workforce reduction and CFO departure introduce uncertainty. A 'hold' recommendation is appropriate pending clarity on the new CFO and the impact of cost-saving measures.

Keywords

Neuronetics, CFO Transition, Steven E. Pfanstiel, NeuroStar Advanced Therapy, Workforce Reduction, Financial Guidance, Restructuring Charges, Medical Technology